What interviewers actually evaluate

Abbott Laboratories leadership interviews test whether candidates understand how leading a diversified healthcare company with four structurally different business segments differs from leadership at a focused medical device company or a pure-play pharmaceutical business – where CEO Robert Ford (who became CEO in March 2020, days before the COVID-19 pandemic declared global emergency status) has led Abbott through the extraordinary COVID diagnostics surge that temporarily made Abbott the world's largest COVID test manufacturer through BinaxNOW, through the FreeStyle Libre CGM franchise's emergence as one of the world's most commercially successful medical devices, and through the 2022 Similac infant formula manufacturing crisis that required leadership in a public health emergency context that tested Abbott's credibility with regulators, consumers, and healthcare providers simultaneously, where Abbott's strategic commitment to maintaining business diversification across medical devices, diagnostics, nutritionals, and established pharmaceuticals creates a leadership challenge of allocating management attention and capital across segments with materially different competitive dynamics, growth rates, and investment return profiles, where the FreeStyle Libre platform's growth into type 2 diabetes (where hundreds of millions of patients have not historically used CGM technology) represents a category expansion opportunity that requires leadership to make sustained investment commitments in market development before the returns become visible in financial results, and where Abbott's global operating presence across more than 160 countries requires leaders who can manage the regulatory, cultural, and operational complexity of a healthcare company with operations spanning diverse regulatory environments and market development stages. Leadership at Abbott spans portfolio strategy and diversification defense (where articulating why Abbott's four-segment model creates value rather than diversification discount requires leaders who can demonstrate how the segments share technology, manufacturing, and commercial capabilities that a focused competitor cannot replicate), FreeStyle Libre category expansion and CGM competitive strategy (where investing ahead of proven type 2 diabetes CGM market development while defending the type 1 core against Dexcom competition requires leadership conviction backed by clear market development evidence), crisis management and regulatory relationship leadership (where the 2022 Similac facility shutdown required Abbott to navigate FDA enforcement action, consumer safety communication, and production restart negotiations under the scrutiny of a national public health crisis), and global healthcare market access leadership (where decisions about which emerging markets merit investment in Established Pharmaceuticals, which regulatory strategies accelerate Libre's global expansion, and how to allocate commercial resources across 160+ country operations require leaders who can assess market development stages and competitive positions across highly diverse healthcare environments).

Start your free Abbott Laboratories Leadership practice session.

What interviewers actually evaluate

Diversified Portfolio Strategy, CGM Category Expansion Leadership, and Regulatory Crisis Management

Abbott leadership interviews probe whether candidates understand how leading through multiple simultaneous strategic challenges across different business segments differs from leading a focused single-business company in the portfolio leadership complexity (Abbott's four segments are each facing distinct competitive and market dynamics simultaneously – Libre must defend against Dexcom while expanding into type 2, Diagnostics must rebuild growth momentum after COVID normalization, Established Pharma must navigate EM currency and regulatory challenges, and Nutritionals must rebuild trust and market position post-formula crisis – and leaders who can hold multiple segment narratives simultaneously, allocate management attention appropriately across competing priorities, and communicate a coherent enterprise strategy that encompasses these diverse dynamics will be more effective than those who can only lead focused single-business narratives), the long-horizon category expansion investment conviction (the type 2 diabetes CGM market opportunity is theoretically massive but requires sustained market development investment in physician education, payer coverage expansion, and patient behavior change before it produces returns that appear in financial results, and leaders who can maintain investment conviction through quarters where the market development spending is visible but the returns are not yet large will build the category that focused competitors who reduce investment during development-phase patience tests will not achieve), and the regulatory relationship leadership integrity requirement (the Similac crisis required Abbott to demonstrate that it was prioritizing infant safety over production speed, cooperating fully with FDA, and communicating transparently with consumers and healthcare providers – leaders who understand how to manage regulatory relationships from a position of genuine compliance commitment rather than managed regulatory risk will build the trust that allows Abbott to return to effective operations more quickly after a quality event than companies whose regulatory relationship is adversarial).

The COVID diagnostics leadership response dimension requires understanding that Robert Ford led Abbott's extraordinary scale-up of BinaxNOW rapid test production – from concept to billions of tests produced – that required manufacturing investment decisions under uncertainty about demand duration, global supply chain coordination under unprecedented strain, and public health communication with government health agencies that positioned Abbott as a critical public health infrastructure partner. This experience created institutional knowledge about rapid scale operations and public-private health partnership that is specific to Abbott's leadership context.

What gets scored in every session

Specific, sentence-level feedback.

Dimension	What it measures	How to answer
Multi-segment portfolio leadership and capital allocation	Do you understand how to lead a diversified healthcare portfolio – how to evaluate capital allocation across four segments with different growth rates and return profiles, what the strategic narrative looks like for justifying Abbott's diversification model to investors who might prefer focused pure-play healthcare companies, and how to allocate management attention across segments where the Libre opportunity may seem to dwarf the nutritionals or established pharma segments in growth impact? We flag leadership answers that describe portfolio management as segment P&L responsibility without engaging with the integrated portfolio strategy and diversification value creation argument that makes Abbott's multi-segment model defensible.	Portfolio capital allocation framework across four different healthcare business models, diversification value creation narrative for investors, management attention allocation between growth segments and stable cash-generating segments
FreeStyle Libre type 2 expansion investment and conviction leadership	Can you describe how to lead the organizational commitment to type 2 diabetes CGM market development – how to maintain R&D and commercial investment in a market where the patient population is 10x type 1 but where adoption rates are early and payback periods are longer, what the leadership narrative looks like for explaining the type 2 investment rationale when quarterly financial results show significant market development spending without proportionate near-term revenue return, and how to track the leading indicators of market development progress (physician adoption rates, payer coverage expansion, patient awareness) that demonstrate investment thesis validation before revenue results confirm it? We score whether your CGM expansion leadership approach engages with the patient market development economics and investor conviction narrative that distinguishes category expansion leadership from defending an established product position.	Type 2 CGM market development investment thesis communication for investor and board audiences, leading indicator tracking for market development progress before revenue confirmation, physician and payer adoption metrics for CGM expansion thesis validation
Regulatory crisis leadership and FDA relationship management	Do you understand how to lead Abbott through a regulatory enforcement event – how to make the production shutdown decision when the risk of continued manufacturing versus the risk of product recall and infant safety exposure requires a judgment call with incomplete information, what the external communication framework looks like for maintaining parent and healthcare provider trust during a formula shortage that Abbott caused through a quality failure, and how to lead the FDA re-inspection and facility restart process in a way that demonstrates genuine quality culture improvement rather than minimal compliance to reopen as quickly as possible? We detect leadership answers that describe regulatory crisis management as communication strategy without engaging with the underlying quality culture and regulatory relationship integrity decisions that determine how effectively Abbott can restore operations and trust.	Production shutdown decision framework under incomplete safety evidence, external communication during regulatory enforcement for consumer and healthcare provider trust, FDA re-inspection leadership that demonstrates quality culture change versus compliance theater
Global healthcare market access and emerging markets leadership	Can you describe how to lead Abbott's global market development strategy – how to allocate commercial resources across 160+ country operations with different healthcare system development stages, what the decision framework looks like for determining which emerging markets merit FreeStyle Libre launch investment versus which should receive established pharmaceuticals focus versus which require only minimal commercial presence, and how to lead the regulatory strategy for accelerating Libre clearances in international markets where the FDA clearance supports but does not substitute for local regulatory approval? We flag leadership answers that describe global operations as international sales management without engaging with the market access investment decisions and regulatory strategy coordination that determine Abbott's global portfolio positioning.	Country market development stage assessment for resource allocation, Libre international regulatory strategy for accelerating clearances in key markets, established pharma versus device commercial resource allocation in EM healthcare systems

How a session works

Step 1: Choose an Abbott Laboratories leadership scenario – multi-segment portfolio strategy and capital allocation, FreeStyle Libre type 2 expansion investment conviction, regulatory crisis leadership and FDA relationship management, or global healthcare market access strategy.

Step 2: The AI interviewer asks realistic Abbott leadership questions: how you would lead the strategic planning discussion with Abbott's board about whether to accelerate investment in the FreeStyle Libre type 2 diabetes expansion at a pace that is ahead of proven market development evidence, including what investment thesis evidence you would present, what the scenario analysis looks like for different adoption rates, and how you would frame the competitive urgency argument against Dexcom's parallel type 2 expansion effort; how you would lead Abbott's communication strategy on the day it became clear that the Sturgis infant formula facility would need to be shut down due to Cronobacter contamination findings, including what you would say publicly, who you would call personally, and how you would sequence the decisions about voluntary recall scope; or how you would explain to an investor analyst why Abbott's four-segment diversification model creates more value than a focused CGM pure-play would achieve, given that some investors argue Abbott's Nutritionals and Established Pharma segments are dragging down the valuation multiple that the Libre growth story deserves.

Step 3: You respond as you would in the actual interview. The system scores your answer on portfolio capital allocation, category expansion investment conviction, regulatory crisis leadership, and global market access strategy.

Step 4: You get sentence-level feedback on what demonstrated genuine Abbott diversified healthcare leadership expertise and what needs stronger type 2 CGM investment thesis construction or regulatory crisis communication framework specificity.

Frequently Asked Questions

Who is Robert Ford and what has his leadership tenure involved?
Robert Ford became Abbott's CEO in March 2020, weeks before the COVID-19 pandemic emergency declaration that would transform his early tenure. Ford led Abbott's extraordinary manufacturing scale-up of BinaxNOW rapid COVID tests, which at its peak made Abbott one of the world's largest COVID diagnostic manufacturers. He has simultaneously led the FreeStyle Libre CGM franchise's global expansion and growing penetration into the type 2 diabetes market, navigated the 2022 Similac infant formula crisis, and maintained Abbott's strategic commitment to its four-segment diversified healthcare model. Ford had previously served as Abbott's President and led the global medical devices business before becoming CEO.

What is Abbott's strategic rationale for maintaining four different business segments?
Abbott defends its diversified model on the basis that the segments share core capabilities including global manufacturing and quality systems, regulatory expertise across multiple FDA product categories, distribution relationships with health systems worldwide, and scientific capabilities in areas like biosensors and diagnostic assay development. The diversification also provides earnings stability – when COVID diagnostics revenue normalized, device growth offset it; when EM pharma faces currency headwinds, the device business provides FX diversification. Critics argue that a focused CGM pure-play would merit a higher valuation multiple, a debate that Abbott management has consistently engaged by pointing to the integrated capabilities and the cash flows from Nutritionals and Established Pharma that fund Device and Diagnostics R&D investment.

What was the Similac infant formula crisis and how did it affect Abbott's leadership?
In February 2022, Abbott recalled several Similac and other infant formula brands manufactured at its Sturgis, Michigan facility following detection of Cronobacter sakazakii bacteria and an FDA inspection that identified unsanitary manufacturing conditions. Abbott voluntarily shut down the Sturgis facility, contributing to a national infant formula shortage that lasted several months, affecting millions of families. The crisis required Abbott leadership to simultaneously manage FDA enforcement action, consumer safety communication, supply shortage emergency response (including importing formula from international Abbott facilities), and facility quality remediation and restart. The episode was one of the most high-profile consumer safety incidents in Abbott's history and required sustained leadership attention to rebuilding regulatory trust, manufacturing quality culture, and consumer confidence.

How does FreeStyle Libre compete against Dexcom in the CGM market?
FreeStyle Libre and Dexcom G7 are the two dominant continuous glucose monitoring systems globally, competing primarily in the type 1 diabetes market and expanding into type 2. Libre has historically differentiated on no-fingerstick calibration requirement (a feature Dexcom has now also achieved), lower cost due to 14-day sensor life versus Dexcom's 10 days, and factory calibration that eliminates the calibration requirement entirely. Abbott has focused on expanding Libre access to type 2 patients through lower prescription barriers and direct pharmacy distribution, while Dexcom has emphasized integration with automated insulin delivery systems (closed-loop therapy) for type 1 patients. The competitive dynamic requires leaders to make simultaneous decisions about type 1 retention and type 2 expansion that may have different product and commercial investment implications.

What does Abbott's global commercial presence look like?
Abbott operates in more than 160 countries, with different segments taking the commercial lead in different markets. In developed markets (US, Europe, Japan), Medical Devices and Diagnostics are the primary commercial drivers, with FreeStyle Libre and Alinity representing major growth platforms. In emerging markets (India, Latin America, Southeast Asia), Established Pharmaceuticals takes the commercial lead, distributing branded generic drugs that are the primary healthcare products for the healthcare systems in those markets. FreeStyle Libre is expanding globally but faces different healthcare system access and reimbursement challenges in each market. Managing this geographic portfolio requires leaders to assess which commercial investments create durable market positions versus which reflect one-time opportunities.